Ultragenyx offloads priority review voucher for $210 million, retains second
Ultragenyx Pharmaceutical has sold a priority review voucher to an unnamed buyer for $210 million. The deal ranks among the highest-priced voucher sales this year. The California company still holds another voucher it can sell.
...
... Need ensure expanded total under 120 words. Let's count. Draft expanded one paragraph: "The sale places Ultragenyx Pharmaceutical among companies that have monetized a priority review voucher, a tradable asset tied to drug development. The buyer remains unnamed, and the $210 million price is described as one of the year's highest for such a deal. Ultragenyx, based in California, still holds another voucher it can sell, leaving open the possibility of a further transaction." Count: The(1) sale2 places3 Ultragenyx4 Pharmaceutical5 among6 companies7 that8 have9 monetized10 a11 priority12 review13 voucher14 a15 tradable16 asset17 tied18 to19 drug20 development21. The22 buyer23 remains24 unnamed25 and26 the27 $21028 million29 price30 is31 described32 as33 one34 of35 the36 year's37 highest38 for39 such40 a41 deal42. Ultragenyx43 based44 in45 California46 still47 holds48 another49 voucher50 it51 can52 sell53 leaving54 open55 the56 possibility57 of58 a59 further60 transaction61. Good. Und